Clin Pharmacokinet 2009; 48 (4): 211-241 REVIEW ARTICLE 0312-5963/09/0004-0211/$49.95/0 ª 2009 Adis Data Information BV. All rights reserved. Drug Interactions with New and Investigational Antiretrovirals Kevin C. Brown, Sunita Paul and Angela D.M. Kashuba School of Pharmacy, Center for AIDS Research Clinical Pharmacology and Analytical Chemistry Core, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA Contents Abstract.......................................................................................................... 212 1. Protease Inhibitors . 212 1.1 Darunavir . 212 1.1.1 Pharmacology . 212 1.1.2 Pharmacokinetics . 214 1.1.3 Drug-Drug Interactions . 215 2. Non-Nucleoside Reverse Transcriptase Inhibitors . 221 2.1 Etravirine . 221 2.1.1 Pharmacology . 221 2.1.2 Pharmacokinetics . 221 2.1.3 Drug-Drug Interactions . 222 2.2 Rilpivirine . 225 2.2.1 Pharmacology . 225 2.2.2 Pharmacokinetics . 225 2.2.3 Drug-Drug Interactions . 225 3. Chemokine Receptor Antagonists . 226 3.1 Maraviroc. 226 3.1.1 Pharmacology . 226 3.1.2 Pharmacokinetics . 227 3.1.3 Drug-Drug Interactions . 227 3.2 Vicriviroc . 229 3.2.1 Pharmacology . 229 3.2.2 Pharmacokinetics . 230 3.2.3 Drug-Drug Interactions . 230 3.3 INCB9471.................................................................................................. 231 3.3.1 Pharmacology . 231 3.3.2 Pharmacokinetics . 231 3.3.3 Drug-Drug Interactions . 231 4. Integrase Inhibitors . 231 4.1 Raltegravir . 231 4.1.1 Pharmacology . 231 4.1.2 Pharmacokinetics . 232 4.1.3 Drug-Drug Interactions . 232 4.2 Elvitegravir . 233 4.2.1 Pharmacology . 233 4.2.2 Pharmacokinetics . 233 4.2.3 Drug-Drug Interactions . 233 212 Brown et al. 5. Maturation Inhibitors . 235 5.1 Bevirimat (PA 457) . 235 5.1.1 Pharmacology . 235 5.1.2 Pharmacokinetics . ..